10-SEP-2025

Non-steroidal MRAs in CKD and heart failure – clinical practice update

Prof. Paola Fioretto

CKD and non-steroidal MRAs:What you need to know

10-SEP-2025

Non-steroidal MRAs in CKD and heart failure – clinical practice update

Prof. Stefan Anker

Exploring non-steroidal MRAs in heart failure treatment

10-SEP-2025

Non-steroidal MRAs in CKD and heart failure – clinical practice update

Prof. Hiddo L. Heerspink

Non-steroidal MRAs and SGLT2 inhibitors – a cardiorenal dream team

10-SEP-2025

Non-steroidal MRAs in CKD and heart failure – clinical practice update

Prof. Linong Ji, Prof. Stefan Anker, Prof. Paola Fioretto, Prof. Hiddo L. Heerspink

Panel discussion

02-JUN-2024

Achieving excellence in the treatment of heart and kidney disease with non-steroidal MRAs

Prof. Paola Fioretto

Removing barriers to treatment of CKD – key characteristics of non-steroidal MRAs

02-JUN-2024

Achieving excellence in the treatment of heart and kidney disease with non-steroidal MRAs

Prof. Pantelis Sarafidis

Improving cardiovascular and kidney outcomes with Finerenone in Type 2 Diabetes

02-JUN-2024

Achieving excellence in the treatment of heart and kidney disease with non-steroidal MRAs

Prof. Stefan Anker

The role for non-steroidal MRAs in CKD and heart failure: Practical considerations and future perspectives

17-APR-2024

Enhancing diagnosis and treatment of CKD

Dr. Beatriz Fernández-Fernández

Removing barriers to the treatment of CKD

17-APR-2024

Enhancing diagnosis and treatment of CKD

Prof. Peter Rossing

Screening and diagnosis of CKD in diabetes – Successful strategies for the clinical practice

17-APR-2024

Enhancing diagnosis and treatment of CKD

Prof. Per-Henrik Groop

The cardiorenal benefits of SGLT2 inhibitors: Insights from across the CKD spectrum

30-NOV-2023

Virtual CVOT Summit 2023 (1): Update on Clinical Guidelines and network Meta-Analyses

Prof. Per-Henrik Groop

Management of CKD in 2023: an update of guidelines